Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

European Urology

Volumn 71, Issue 1, 2017, Pages 96-108

  Antoni, Sebastien ^a   Ferlay, Jacques ^a   Soerjomataram, Isabelle ^a   Znaor, Ariana ^a   Jemal, Ahmedin ^b   Bray, Freddie ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

Bladder; Cancer; Incidence; Mortality; Statistics

Indexed keywords

AFRICA; AFRICA SOUTH OF THE SAHARA; ASIA; AUSTRALIA AND NEW ZEALAND; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CARIBBEAN; CENTRAL AFRICA; CENTRAL AMERICA; DEVELOPED COUNTRY; FEDERATED STATES OF MICRONESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANESIA; NORTH AFRICA; NORTH AMERICA; POLYNESIA; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SOUTH AFRICA; SOUTH AMERICA; SOUTHERN EUROPE; TREND STUDY; WESTERN EUROPE; BLADDER TUMOR; GLOBAL HEALTH; INCIDENCE; INTERNATIONAL COOPERATION; MORTALITY; REGISTER; RISK FACTOR; SMOKING; STATISTICS AND NUMERICAL DATA; TRENDS;

FEMALE; GLOBAL HEALTH; HUMANS; INCIDENCE; INTERNATIONALITY; MALE; REGISTRIES; RISK FACTORS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 84979707958     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.06.010     Document Type: Review

References (72)

1. [1] GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer Web site. http://globocan.iarc.fr.
2. [2] Burger, M., Catto, J.W., Dalbagni, G., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63 (2013), 234–241.
3. [3] Ng, M., Freeman, M.K., Fleming, T.D., et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 311 (2014), 183–192.
4. [4] Parkin, D.M., The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118 (2006), 3030–3044.
5. [5] Parkin, D.M., The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 218 (2008), 12–20.
6. [6] Cancer incidence in five continents, Vol. I–X. International Agency for Research on Cancer Web site. http://ci5.iarc.fr/CI5I-X.
7. [7] Bray, F., Ferlay, J., Laversanne, M., et al. Cancer incidence in five continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer 137 (2015), 2060–2071.
8. [8] Forman, D., Bray, F., Brewster, D.H., et al. Cancer incidence in five continents, X, 2013, IARC, Lyon, France.
9. [9] Cancer incidence in five continents, CI5plus. IARC CancerBase No. 9. International Agency for Research on Cancer Web site. http://ci5.iarc.fr.
10. [10] NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic Countries, Version 7.1. Association of the Nordic Cancer Registries. Danish Cancer Society Web site. http://www.ancr.nu.
11. [11] European Cancer Observatory: Cancer incidence, mortality, prevalence and survival in Europe. European Network of Cancer Registries, International Agency for Research on Cancer Web site. http://eco.iarc.fr/.
12. [12] Croatian National Cancer Registry. Cancer in Croatia 2012 Web site. http://www.hzjz.hr/sluzbe/sluzba-za-epidemiologiju/odjel-za-nadzor-i-istrazivanje-ne-zaraznih-bolesti/odsjek-za-zlocudne-bolesti-s-registrom-za-rak.
13. [13] Czech National Cancer Registry. Cancer incidence 2010 in the Czech Republic Web site. http://www.uzis.cz/.
14. [15] Dimitrova N, Vukov M, Valerianova Z. Report cancer incidence in Bulgaria 2011. Sofia, Bulgaria: Bulgarian National Cancer Registry; 2013.
15. [16] National Cancer Registry Ireland Web site. http://www.ncri.ie/.
16. [17] Moscow Research Oncological Institute, Russian Federation Web site. http://www.oncology.ru.
17. [18] UK, England, Office for National Statistics Web site. http://www.ons.gov.uk/ons/.
18. [19] Surveillance, Epidemiology, and End Results Program Research Data (1973-2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch Web site. http://seer.cancer.gov/.
19. [20] Republic of Korea National Cancer Centre Web site. http://www.ncc.re.kr/english/infor/kccr.jsp.
20. [21] Australian Cancer Database. Australian Institute of Health and Welfare Web site. http://www.aihw.gov.au.
21. [22] New Zealand National Ministry of Health Web site. http://www.nzhis.govt.nz.
22. [23] WHO Mortality Database World Health Organisation Web site. http://www.who.int/healthinfo/statistics/mortality_rawdata/en/index.html.
23. [24] Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
24. [25] United Nations Development Programme. Human Development Index (HDI) Web site. http://hdr.undp.org/en/content/human-development-index-hdi.
25. [26] Segi, M., Cancer mortality for selected sites in 24 countries (1950-57). 1960, Department of Public Health, Tohoku University of Medicine, Sendai, Japan.
26. [27] Clegg, L.X., Hankey, B.F., Tiwari, R., Feuer, E.J., Edwards, B.K., Estimating average annual per cent change in trend analysis. Stat Med 28 (2009), 3670–3682.
27. [28] Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.
28. [29] R Development Core Team. R: A language and environment for statistical computing [computer programme]. Vienna, Austria: R Foundation for Statistical Computing; 2014.
29. [30] Cumberbatch, M.G., Rota, M., Catto, J.W., La, V.C., The role of tobacco smoke in bladder and kidney carcinogenesis: A comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol 70 (2016), 458–466.
30. [31] Freedman, N.D., Silverman, D.T., Hollenbeck, A.R., Schatzkin, A., Abnet, C.C., Association between smoking and risk of bladder cancer among men and women. JAMA 306 (2011), 737–745.
31. [32] Park, S., Jee, S.H., Shin, H.R., et al. Attributable fraction of tobacco smoking on cancer using population-based nationwide cancer incidence and mortality data in Korea. BMC Cancer, 14, 2014, 406.
32. [33] Agudo, A., Bonet, C., Travier, N., et al. Impact of cigarette smoking on cancer risk in the European prospective investigation into cancer and nutrition study. J Clin Oncol 30 (2012), 4550–4557.
33. [34] Moolgavkar, S.H., Stevens, R.G., Smoking and cancers of bladder and pancreas: risks and temporal trends. J Natl Cancer Inst 67 (1981), 15–23.
34. [35] Centres for Disease Control and Prevention. Trends in current cigarette smoking among high school students and adults, United States, 1965-2011. Centres for Disease Control and Prevention Web site. http://www.cdc.gov/tobacco/data_statistics/tables/trends/cig_smoking.
35. [36] Regidor, E., Gutierrez-Fisac, J.L., de lS, I., Fernandez, E., Trends in principal cancer risk factors in Spain. Ann Oncol, 21(Suppl 3), 2010 iii37-42.
36. [37] Eriksen, M., Mackay, J., Schluger, N., Islami Gomeshtapeh, F., Drope, J., The tobacco atlas. 5, 2015, American Cancer Society, Atlanta, GA.
37. [38] Steinmann, P., Keiser, J., Bos, R., Tanner, M., Utzinger, J., Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6 (2006), 411–425.
38. [39] Parkin, D.M., Sitas, F., Chirenje, M., Stein, L., Abratt, R., Wabinga, H., Part I: Cancer in indigenous Africans—burden, distribution, and trends. Lancet Oncol 9 (2008), 683–692.
39. [40] Salem, H.K., Mahfouz, S., Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade. Urology 79 (2012), 379–383.
40. [41] Felix, A.S., Soliman, A.S., Khaled, H., et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 19 (2008), 421–429.
41. [42] Gouda, I., Mokhtar, N., Bilal, D., El-Bolkainy, T., El-Bolkainy, N.M., Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst 19 (2007), 158–162.
42. [43] El-Zanaty F, Way AA. Report Egypt Demographic and Health Survey 2005. Cairo, Egypt: Ministry of Health and Population, National Population Council, El-Zanaty and Associates, and ORC Macro; 2006.
43. [44] World Health Organisation. WHO Report on the Global Tobacco Epidemic, Country profile: Malawi Web site. http://www.who.int/tobacco/surveillance/policy/country_profile/mwi.pdf.
44. [45] Makaula, P., Sadalaki, J.R., Muula, A.S., Kayuni, S., Jemu, S., Bloch, P., Schistosomiasis in Malawi: A systematic review. Parasit Vectors, 7, 2014, 570.
45. [46] Cogliano, V.J., Baan, R., Straif, K., et al. Preventable exposures associated with human cancers. J Natl Cancer Inst 103 (2011), 1827–1839.
46. [47] Vlaanderen, J., Straif, K., Ruder, A., et al. Tetrachloroethylene exposure and bladder cancer risk: a meta-analysis of dry-cleaning-worker studies. Environ Health Perspect 122 (2014), 661–666.
47. [48] Rushton, L., Hutchings, S.J., Fortunato, L., et al. Occupational cancer burden in Great Britain. Br J Cancer 107:Suppl 1 (2012), S3–S7.
48. [49] Purdue, M.P., Hutchings, S.J., Rushton, L., Silverman, D.T., The proportion of cancer attributable to occupational exposures. Ann Epidemiol 25 (2015), 188–192.
49. [50] Marshall, G., Ferreccio, C., Yuan, Y., et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99 (2007), 920–928.
50. [51] Steinmaus, C.M., Ferreccio, C., Romo, J.A., et al. Drinking water arsenic in northern chile: high cancer risks 40 years after exposure cessation. Cancer Epidemiol Biomarkers Prev 22 (2013), 623–630.
51. [52] Antonova, O., Toncheva, D., Grigorov, E., Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolising enzymes. J BUON 20 (2015), 1397–1406.
52. [53] Pesch, B., Gawrych, K., Rabstein, S., et al. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort. Cancer Epidemiol Biomarkers Prev 22 (2013), 2055–2065.
53. [54] Jacobs, B.L., Montgomery, J.S., Zhang, Y., Skolarus, T.A., Weizer, A.Z., Hollenbeck, B.K., Disparities in bladder cancer. Urol Oncol 30 (2012), 81–88.
54. [55] Report Caisse nationale de l'assurance maladie. Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI,;1; 2011. January 7, 2016; Paris, France.
55. [56] Grosse, Y., Loomis, D., Lauby-Secretan, B., et al. Carcinogenicity of some drugs and herbal products. Lancet Oncol 14 (2013), 807–808.
56. [57] Lewis, J.D., Habel, L.A., Quesenberry, C.P., et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314 (2015), 265–277.
57. [58] Levin, D., Bell, S., Sund, R., et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58 (2015), 493–504.
58. [59] Turner, R.M., Kwok, C.S., Chen-Turner, C., Maduakor, C.A., Singh, S., Loke, Y.K., Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis. Br J Clin Pharmacol 78 (2014), 258–273.
59. [60] Larre, S., Catto, J.W., Cookson, M.S., et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol 63 (2013), 1049–1058.
60. [61] Kamat, A.M., Hegarty, P.K., Gee, J.R., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol 63 (2013), 4–15.
61. [62] Marcos-Gragera, R., Mallone, S., Kiemeney, L.A., et al. Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. Eur J Cancer 51 (2015), 2217–2230.
62. [63] Leal, J., Luengo-Fernandez, R., Sullivan, R., Witjes, J.A., Economic burden of bladder cancer across the European Union. Eur Urol 69 (2016), 438–447.
63. [64] Babjuk, M., Burger, M., Zigeuner, R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 64 (2013), 639–653.
64. [65] Gakis, G., Efstathiou, J., Lerner, S.P., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63 (2013), 45–57.
65. [66] Karim-Kos, H.E., de, V.E., Soerjomataram, I., Lemmens, V., Siesling, S., Coebergh, J.W., Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44 (2008), 1345–1389.
66. [67] Malmstrom, P.U., Why has the survival of patients with bladder cancer not improved?. BJU Int 101 (2008), 267–269.
67. [68] Janssen, F., Kunst, A.E., ICD coding changes and discontinuities in trends in cause-specific mortality in six European countries, 1950-99. Bull World Health Organ 82 (2004), 904–913.
68. [69] Nielsen, M.E., Smith, A.B., Meyer, A.M., et al. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988-2006. Cancer 120 (2014), 86–95.
69. [70] Scottish Cancer Registry Web site. http://www.isdscotland.org/Health-Topics/Cancer/Scottish-Cancer-Registry.asp.
70. [71] International rules for multiple primary cancers (ICD-0 ed. 3). Eur J Cancer Prev 2005; 14:307-8.
71. [72] World Health Organisation. Global Status Report on Noncommunicable Diseases., 2014, WHO, Geneva (Switzerland).
72. [73] Antoni, S., Soerjomataram, I., Moller, B., Bray, F., Ferlay, J., An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence. Bull World Health Organ 94 (2016), 174–184.